Osimertinib + Savolitinib
D5084C00009
Phase 2 small_molecule active
Quick answer
Osimertinib + Savolitinib for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active